Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
26.58
+2.68 (11.21%)
At close: Aug 13, 2025, 4:00 PM
26.68
+0.10 (0.38%)
After-hours: Aug 13, 2025, 6:19 PM EDT
Apellis Pharmaceuticals Employees
As of December 31, 2024, Apellis Pharmaceuticals had 710 total employees, including 705 full-time and 5 part-time employees. The number of employees increased by 4 or 0.57% compared to the previous year.
Employees
710
Change (1Y)
4
Growth (1Y)
0.57%
Revenue / Employee
$1,062,886
Profits / Employee
-$321,372
Market Cap
3.36B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
APLS News
- 11 days ago - Apellis Pharmaceuticals, Inc. (APLS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Apellis Pharmaceuticals: The Picture Becomes Clearer - Seeking Alpha
- 13 days ago - Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 15 days ago - FDA Approval For Empaveli Marks Key Milestone In Apellis' Rare Disease Portfolio - Benzinga
- 15 days ago - FDA Approves Apellis' EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older - GlobeNewsWire
- 20 days ago - Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting - GlobeNewsWire
- 6 weeks ago - Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan) - PRNewsWire